Abstract:Background Remarkable advances for clinical diagnosis and treatment in cancers including lung cancer involve cell-free circulating tumor DNA (ctDNA) detection through next generation sequencing. However, before the sensitivity and specificity of ctDNA detection can be widely recognized, the consistency of mutations in tumor tissue and ctDNA should be evaluated. The urgency of this consistency is extremely obvious in lung cancer to which great attention has been paid to in liquid biopsy field. Methods We have developed an approach named systematic error correction sequencing (Sec-Seq) to improve the evaluation of sequence alterations in circulating cell-free DNA. Averagely 10 ml preoperative blood samples were collected from 30 patients containing pulmonary space occupying pathological changes by traditional clinic diagnosis. cfDNA from plasma, genomic DNA from white blood cells, and genomic DNA from solid tumor of above patients were extracted and constructed as libraries for each sample before subjected to sequencing by a panel contains 50 cancer-associated genes encompassing 29 kb by custom probe hybridization capture with average depth >40000, 7000, or 6300 folds respectively. Results Detection limit for mutant allele frequency in our study was 0.1%. The sequencing results were analyzed by bioinformatic expertise based on our previous studies on the baseline mutation profiling of circulating cell-free DNA and the clinicopathological data of these patients. Among all the lung cancer patients, 78% patients were predicted as positive by ctDNA sequencing when the shreshold was defined as at least one of the hotspot mutations detected in the blood (ctDNA) was also detected in tumor tissue. Pneumonia and pulmonary tuberculosis were detected as negative according to the above standard. When evaluating all hotspots in driver genes in the panel, 24% mutations detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). When evaluating all genetic variations in the panel, including all the driver genes and passenger genes, 28% detected in tumor tissue (tDNA) were also detected in patients blood (ctDNA). Positive detection rates of plasma ctDNA in stage I lung cancer patients is 85%, compared with 17% of tumor biomarkers. Conclusion We demonstrated the importance of sequencing both circulating cell-free DNA and genomic DNA in tumor tissue for ctDNA detection in lung cancer currently. We also determined and confirmed the consistency of ctDNA and tumor tissue through NGS according to the criteria explored in our studies. Our strategy can initially distinguish the lung cancer from benign lesions of lung. Our work shows that the consistency will be benefited from the optimization in sensitivity and specificity in ctDNA detection.

Integrated digital error suppression for improved detection of circulating tumor DNA

Enhanced detection of circulating tumor DNA by fragment size analysis

Ultrasensitive Detection of Circulating Tumor DNA in Lymphoma via Targeted Hybridization Capture and Deep Sequencing of Barcoded Libraries

Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing

Increased Detection of Circulating Tumor DNA by Short Fragment Enrichment

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoring

Circulating tumor DNA analysis for tumor diagnosis

"Liquid biopsy"-ctDNA detection with great potential and challenges.

Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer

The Early Diagnosis in Lung Cancer by the Detection of Circulating Tumor DNA

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma

Application of Circulating Tumor DNA in Precision Diagnosis and Treatment of Colorectal Cancer

Advancing cancer MRD monitoring through tumor whole-genome informed, duplex ctDNA sequencing.

Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology

A novel virtual barcode strategy for accurate panel-wide variant calling in circulating tumor DNA

Toward liquid biopsies in cancer treatment: application of circulating tumor DNA

Emerging ctDNA detection strategies in clinical cancer theranostics